
April 10, 2023
RegMed Investors (RMi) Research Note: Q4 and FY22 earnings reporting
April 10, 2023
RegMed Investors’ (RMi) closing bell: sector hops back on the spinning tea cup amusement rides; but I am not entertained
April 10, 2023
RegMed Investors’ (RMi) pre-open: sector share pricing sustainability needed
April 6, 2023
RegMed Investors’ (RMi) pre-open: Thursday will cap off a shortened trading week with the market closed for Good Friday
April 5, 2023
RegMed Investors’ (RMi) closing bell: the cell and gene therapy sector just can’t get a break
April 5, 2023
RegMed Investors’ (RMi) pre-open: lookin’ for love, the cell and gene therapy sector even welcomes any algos
April 4, 2023
RegMed Investors’ (RMi) closing bell: the pain trade
April 4, 2023
RegMed Investors’ (RMi) pre-open: warning
April 3, 2023
RegMed Investors’ (RMi) closing bell: Q2 starts as the cell and gene therapy sector falters
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors